Skip to main content
Clinical Trials/NCT00815594
NCT00815594UnknownPhase 4

Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab

Capital Medical University1 site in 1 country30 target enrollmentStarted: December 1, 2008Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 4
Sponsor
Enrollment
30
Locations
1
Primary Endpoint
bleb vascular change

Study Overview

Brief Summary

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Glaucoma patients after trabeculectomy whose bleb is hyperaemia

Exclusion Criteria

  • Affected eye has normal IOP
  • Not allergic with Avastin

Outcomes

Primary Outcomes

bleb vascular change

Time Frame: one day, one week, one month

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Capital Medical University
Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials